HER2/neu

Из Википедије, слободне енциклопедије
Иди на навигацију Иди на претрагу
ERBB2
Trastuzumab Fab-HER2 complex 1N8Z.png
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifikatori
AlijasiERBB2
Spoljašnji IDOMIM: 164870 HomoloGene: 3273 GeneCards: ERBB2
EC number2.7.10.1
Obrazac RNK izražavanja
PBB GE ERBB2 210930 s at.png

PBB GE ERBB2 216836 s at.png
More reference expression data
Ortolozi
VrsteČovekMiš
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001005862
NM_001289936
NM_001289937
NM_001289938
NM_004448

n/a

RefSeq (protein)

NP_001005862
NP_001276865
NP_001276866
NP_001276867
NP_004439

n/a

Location (UCSC)n/an/a
PubMed search[1]n/a
Wikidata
View/Edit Human

Receptorska tirozinska proteinska kinaza erbB-2 (CD340, klaster diferencijacije 340, proto-onkogen Neu, Erbb2 (glodari), ili ERBB2 (ljudi)) protein je koji je kod ljudi kodiran ERBB2 genom. Ona se često naziva HER2 (od енгл. human epidermal growth factor receptor 2) ili HER2/neu.

HER2 je član familije receptora epidermalnih faktora rasta (HER/EGFR/ERBB). Amplifikacija ili prekomerno izražavanje ovog onkogena ima važnu ulogu u razviću i progresiji pojedinih agresivnih tipova raka dojke. Zadnjih godina ovaj protein je postao važan biomarker ili meta u lečenju oko 30% pacijenata sa kancerom dojke.[2][3]

HER2 interakcije[уреди]

HER2/neu formira interakcije sa:

Reference[уреди]

  1. ^ „Human PubMed Reference:”. 
  2. ^ Mitri Z, Constantine T, O'Regan R (2012). „The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy”. Chemother Res Pract. 2012: 743193. PMC 3539433Слободан приступ. PMID 23320171. doi:10.1155/2012/743193. 
  3. ^ Burstein HJ (2005). „The distinctive nature of HER2-positive breast cancers”. N. Engl. J. Med. 353 (16): 1652—4. PMID 16236735. doi:10.1056/NEJMp058197. 
  4. ^ Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ (2002). „ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas”. The Journal of Biological Chemistry. 277 (25): 22692—8. PMID 11950845. doi:10.1074/jbc.M201975200. 
  5. ^ Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, Dunach M, Neckers LM (2001). „Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription”. Cancer Research. 61 (4): 1671—7. PMID 11245482. 
  6. ^ Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S (1995). „c-erbB-2 gene product directly associates with beta-catenin and plakoglobin”. Biochemical and Biophysical Research Communications. 208 (3): 1067—72. PMID 7702605. doi:10.1006/bbrc.1995.1443. 
  7. ^ Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, Pelkey KA, Yang DJ, Xiong WC, Salter MW, Mei L (2000). „Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses”. Neuron. 26 (2): 443—55. PMID 10839362. doi:10.1016/s0896-6273(00)81176-9. 
  8. 8,0 8,1 Jaulin-Bastard F, Saito H, Le Bivic A, Ollendorff V, Marchetto S, Birnbaum D, Borg JP (2001). „The ERBB2/HER2 receptor differentially interacts with ERBIN and PICK1 PSD-95/DLG/ZO-1 domain proteins”. The Journal of Biological Chemistry. 276 (18): 15256—63. PMID 11278603. doi:10.1074/jbc.M010032200. 
  9. ^ Bilder D, Birnbaum D, Borg JP, Bryant P, Huigbretse J, Jansen E, Kennedy MB, Labouesse M, Legouis R, Mechler B, Perrimon N, Petit M, Sinha P (2000). „Collective nomenclature for LAP proteins”. Nature Cell Biology. 2 (7): E114. doi:10.1038/35017119. 
  10. ^ Huang YZ, Zang M, Xiong WC, Luo Z, Mei L (2003). „Erbin suppresses the MAP kinase pathway”. The Journal of Biological Chemistry. 278 (2): 1108—14. PMID 12379659. doi:10.1074/jbc.M205413200. 
  11. 11,0 11,1 Schulze WX, Deng L, Mann M (2005). „Phosphotyrosine interactome of the ErbB-receptor kinase family”. Molecular Systems Biology. 1: 2005.0008. PMC 1681463Слободан приступ. PMID 16729043. doi:10.1038/msb4100012. 
  12. ^ Bourguignon LY, Zhu H, Zhou B, Diedrich F, Singleton PA, Hung MC (2001). „Hyaluronan promotes CD44v3-Vav2 interaction with Grb2-p185(HER2) and induces Rac1 and Ras signaling during ovarian tumor cell migration and growth”. The Journal of Biological Chemistry. 276 (52): 48679—92. PMID 11606575. doi:10.1074/jbc.M106759200. 
  13. 13,0 13,1 Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE (1998). „ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner”. Molecular and Cellular Biology. 18 (9): 5042—51. PMC 109089Слободан приступ. PMID 9710588. doi:10.1128/mcb.18.9.5042. 
  14. ^ Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, Yarden Y, Neckers L (2001). „Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90”. The Journal of Biological Chemistry. 276 (5): 3702—8. PMID 11071886. doi:10.1074/jbc.M006864200. 
  15. ^ Jeong JH, An JY, Kwon YT, Li LY, Lee YJ (2008). „Quercetin-induced ubiquitination and down-regulation of Her-2/neu”. Journal of Cellular Biochemistry. 105 (2): 585—95. PMC 2575035Слободан приступ. PMID 18655187. doi:10.1002/jcb.21859. 
  16. ^ Grant SL, Hammacher A, Douglas AM, Goss GA, Mansfield RK, Heath JK, Begley CG (2002). „An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells”. Oncogene. 21 (3): 460—74. PMID 11821958. doi:10.1038/sj.onc.1205100. 
  17. ^ Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D (2003). „Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein”. Molecular Cancer Research. 1 (10): 765—75. PMID 12939402. 
  18. ^ Schroeder JA, Thompson MC, Gardner MM, Gendler SJ (2001). „Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland”. The Journal of Biological Chemistry. 276 (16): 13057—64. PMID 11278868. doi:10.1074/jbc.M011248200. 
  19. ^ Gout I, Dhand R, Panayotou G, Fry MJ, Hiles I, Otsu M, Waterfield MD (1992). „Expression and characterization of the p85 subunit of the phosphatidylinositol 3-kinase complex and a related p85 beta protein by using the baculovirus expression system”. The Biochemical Journal. 288 ( Pt 2) (2): 395—405. PMC 1132024Слободан приступ. PMID 1334406. doi:10.1042/bj2880395. 
  20. ^ Peles E, Levy RB, Or E, Ullrich A, Yarden Y (1991). „Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma”. The EMBO Journal. 10 (8): 2077—86. PMC 452891Слободан приступ. PMID 1676673. 
  21. ^ Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL (1991). „Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas”. Proceedings of the National Academy of Sciences of the United States of America. 88 (23): 10435—9. Bibcode:1991PNAS...8810435A. PMC 52943Слободан приступ. PMID 1683701. doi:10.1073/pnas.88.23.10435. 
  22. ^ Wong L, Deb TB, Thompson SA, Wells A, Johnson GR (1999). „A differential requirement for the COOH-terminal region of the epidermal growth factor (EGF) receptor in amphiregulin and EGF mitogenic signaling”. The Journal of Biological Chemistry. 274 (13): 8900—9. PMID 10085134. doi:10.1074/jbc.274.13.8900. 

Literatura[уреди]

Spoljašnje veze[уреди]